Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Divis Lab gets green...

    Divis Lab gets green nod for 100 crore modernisation project

    Written by Ruby Khatun Khatun Published On 2017-08-15T09:51:12+05:30  |  Updated On 15 Aug 2017 9:51 AM IST
    Divis Lab gets green nod for 100 crore modernisation project

    New Delhi: Divis Laboratories has received environment clearance for the modernisation of its bulk drug unit in Visakhapatnam that will entail a cost of 100 crore.


    The company wants to modernise one of the two units by shifting non-production activities to proposed new area and meet all modern production facility compliances for achieving export targets.


    The proposal was first vetted by an expert panel and based on its recommendations, the Union environment ministry last week gave the final environment clearance (EC) to Divi's Laboratories for the modernisation project. The approval is subject to compliance of specific and general conditions, said the EC letter issued to the company.


    The company has informed that the proposed project is estimated to cost about 100 crore and will generate employment for nearly 8,000 people.


    A t present, the company has a land area of 387 acres, and an additional 108.59 acres will be used for the proposed modernisation, which will be carried out in two phases. The phase-I works would include construction of production blocks and ancillary works, while the phase-II would focus on production-related utilities


    Among conditions specified, the company has been asked to develop a green belt in 33 per cent of the area, plant 1,000 trees a year for five years and install an online monitoring system for measuring pollutants within the treatment unit.


    During the proposed modernisation, the company said that there will be no change in production capacity, number of products, water consumption, wastewater generation and pollution loads.


    Currently, Divi's Laboratories has two manufacturing facilities, one each in Nalgonda and Visakhapatnam districts.


    Both facilities are primarily engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), custom synthesis of API and advanced intermediates for discovery compounds for big pharma companies.

    100 croreactive pharmaceutical ingredientsAPIapprovalbulk drug unitDivis LaboratoriesDivis LabsEnvironment Clearancegreen nodmodernisationNalgondaprojectsVisakhapatnam
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok